Quarterly Business Update and Appendix 4C - September 2025
| Stock | Inoviq Ltd (IIQ.ASX) |
|---|---|
| Release Time | 29 Oct 2025, 8:58 a.m. |
| Price Sensitive | Yes |
Inoviq Secures Funding to Accelerate Ovarian Cancer Test and Therapeutics
- Exclusive worldwide licence for exosomal ovarian cancer biomarker from UniQuest
- Potent in vitro tumour-killing activity of CAR-NK-exosomes against TNBC cells
- CAR-T-exosome in vitro cancer-killing activity and EXO-ACE production data published
Inoviq Ltd has put in place important building blocks during the quarter and progressed planning for a clinical validation study to support a Laboratory Developed Test for its exosome-based ovarian cancer screening test. The company secured an exclusive worldwide licence from The University of Queensland's commercialisation company UniQuest to develop and commercialise novel exosomal biomarkers for the early detection of ovarian cancer. Inoviq's ovarian cancer test achieved 100% sensitivity for early-stage ovarian cancer detection and over 99.6% specificity, showing its potential to be developed as an ovarian cancer screening test. The company is now funded to progress its ovarian cancer test to LDT stage by the end of 2026 and is in advanced discussions with strategic partners. Inoviq also reported positive results from in vitro validation studies of its CAR-NK-exosome therapeutic candidate at Peter Mac, confirming the potent anti-tumour activity of its CAR-NK-exosomes in triple-negative breast cancer cells. Proof-of-concept data were also published demonstrating the in vitro cancer-killing efficacy of Inoviq's engineered CAR-T-exosomes and the scalability of its proprietary EXO-ACE manufacturing platform. The company completed a $9.5 million placement to institutional and sophisticated investors to fund the development of its ovarian cancer test and exosome therapeutic program.
Inoviq is progressing development of its CAR-NK-EVs to in vivo efficacy studies in animal models of TNBC commencing in Q4 CY2025 and expected to deliver initial results by the end of the year.
Inoviq's FY26 priorities include expanding its business and growing revenues, advancing its ovarian cancer screening test toward commercialisation, progressing its CAR-exosome therapy into in vivo efficacy studies for breast cancer, and entering into strategic partnerships to accelerate commercialisation of its diagnostic technologies.